Does the media prefer COGT or SNDX?

In the previous week, Cogent Biosciences had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Cogent Biosciences and 6 mentions for Syndax Pharmaceuticals. Cogent Biosciences' average media sentiment score of 1.53 beat Syndax Pharmaceuticals' score of 1.03 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or SNDX?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Syndax Pharmaceuticals' score of 1.03 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or CGON?

In the previous week, CG Oncology had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 13 mentions for CG Oncology and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat CG Oncology's score of 0.93 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XENE or SNDX?

In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.33 beat Syndax Pharmaceuticals' score of 1.03 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or SNDX?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Syndax Pharmaceuticals. Dianthus Therapeutics' average media sentiment score of 1.39 beat Syndax Pharmaceuticals' score of 1.03 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$18.80 -0.25 (-1.31%)

As of 01:33 PM Eastern

Compare

SNDX vs. COGT, MIRM, CGON, XENE, and DNTH

Should you buy Syndax Pharmaceuticals stock or one of its competitors? MarketBeat compares Syndax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syndax Pharmaceuticals include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Xenon Pharmaceuticals (XENE), and Dianthus Therapeutics (DNTH). These companies are all part of the "biotechnology" industry.

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Cogent Biosciences presently has a consensus price target of $45.90, indicating a potential upside of 17.60%. Syndax Pharmaceuticals has a consensus price target of $42.55, indicating a potential upside of 126.31%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Cogent Biosciences has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Cogent Biosciences' return on equity of -104.27% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Syndax Pharmaceuticals has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Syndax Pharmaceuticals	$172.35M	9.67	-$285.42M	-$2.79	N/A

In the previous week, Cogent Biosciences had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 9 mentions for Cogent Biosciences and 6 mentions for Syndax Pharmaceuticals. Cogent Biosciences' average media sentiment score of 1.53 beat Syndax Pharmaceuticals' score of 1.03 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Syndax Pharmaceuticals beats Cogent Biosciences on 8 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Syndax Pharmaceuticals has a net margin of -111.88% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Syndax Pharmaceuticals' score of 1.03 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	11.17	-$23.36M	-$13.61	N/A
Syndax Pharmaceuticals	$172.35M	9.67	-$285.42M	-$2.79	N/A

Mirum Pharmaceuticals currently has a consensus target price of $143.40, indicating a potential upside of 37.48%. Syndax Pharmaceuticals has a consensus target price of $42.55, indicating a potential upside of 126.31%. Given Syndax Pharmaceuticals' higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to CG Oncology?

Syndax Pharmaceuticals (NASDAQ:SNDX) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CG Oncology has lower revenue, but higher earnings than Syndax Pharmaceuticals. CG Oncology is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.67	-$285.42M	-$2.79	N/A
CG Oncology	$5.07M	1,197.10	-$160.99M	-$2.33	N/A

Syndax Pharmaceuticals presently has a consensus target price of $42.55, suggesting a potential upside of 126.31%. CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 18.75%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. CG Oncology's return on equity of -23.33% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, CG Oncology had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 13 mentions for CG Oncology and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat CG Oncology's score of 0.93 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Summary

CG Oncology beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Xenon Pharmaceuticals' return on equity of -49.23% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.33 beat Syndax Pharmaceuticals' score of 1.03 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	798.75	-$345.91M	-$4.70	N/A
Syndax Pharmaceuticals	$172.35M	9.67	-$285.42M	-$2.79	N/A

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus target price of $77.20, indicating a potential upside of 24.58%. Syndax Pharmaceuticals has a consensus target price of $42.55, indicating a potential upside of 126.31%. Given Syndax Pharmaceuticals' higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Xenon Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Syndax Pharmaceuticals. Dianthus Therapeutics' average media sentiment score of 1.39 beat Syndax Pharmaceuticals' score of 1.03 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals has a net margin of -111.88% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dianthus Therapeutics currently has a consensus target price of $117.82, suggesting a potential upside of 12.29%. Syndax Pharmaceuticals has a consensus target price of $42.55, suggesting a potential upside of 126.31%. Given Syndax Pharmaceuticals' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Dianthus Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,293.29	-$162.34M	-$4.13	N/A
Syndax Pharmaceuticals	$172.35M	9.67	-$285.42M	-$2.79	N/A

Dianthus Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

Summary

Dianthus Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.67B	$3.51B	$6.80B	$12.67B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-6.74	7.37	282.15	25.05
Price / Sales	9.67	1,199.53	571.19	79.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	25.41	16.86	11.03	6.18
Net Income	-$285.42M	-$12.56M	$3.49B	$347.72M
7 Day Performance	-8.38%	-1.04%	0.31%	0.64%
1 Month Performance	-13.84%	-7.80%	-4.41%	-3.82%
1 Year Performance	88.38%	48.79%	62.76%	20.08%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	3.0053 of 5 stars	$18.80 -1.3%	$42.55 +126.3%	+90.9%	$1.67B	$172.35M	N/A	110	Positive News Upcoming Earnings
COGT Cogent Biosciences	2.1786 of 5 stars	$38.96 -5.8%	$45.90 +17.8%	+241.5%	$6.66B	N/A	N/A	80	Positive News Upcoming Earnings
MIRM Mirum Pharmaceuticals	3.3492 of 5 stars	$105.67 -6.1%	$143.40 +35.7%	+103.7%	$6.44B	$569.61M	N/A	140	Positive News
CGON CG Oncology	3.2619 of 5 stars	$71.07 -2.7%	$81.73 +15.0%	+170.6%	$6.27B	$5.07M	N/A	61	Positive News Upcoming Earnings
XENE Xenon Pharmaceuticals	3.2322 of 5 stars	$62.67 -2.4%	$77.20 +23.2%	+105.5%	$6.06B	$7.50M	N/A	210	Positive News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. COGT, MIRM, CGON, XENE, and DNTH

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to CG Oncology?

Summary

How does Syndax Pharmaceuticals compare to Xenon Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. COGT, MIRM, CGON, XENE, and DNTH

How does Syndax Pharmaceuticals compare to Cogent Biosciences?

Do analysts rate COGT or SNDX?

Is COGT or SNDX more profitable?

Which has stronger earnings & valuation, COGT or SNDX?

Does the media prefer COGT or SNDX?

Which has more risk and volatility, COGT or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or SNDX more profitable?

Which has more risk & volatility, MIRM or SNDX?

Does the media refer more to MIRM or SNDX?

Which has stronger earnings & valuation, MIRM or SNDX?

Do analysts prefer MIRM or SNDX?

Summary

How does Syndax Pharmaceuticals compare to CG Oncology?

Do insiders & institutionals hold more shares of SNDX or CGON?

Which has stronger valuation & earnings, SNDX or CGON?

Do analysts rate SNDX or CGON?

Is SNDX or CGON more profitable?

Does the media favor SNDX or CGON?

Which has more risk & volatility, SNDX or CGON?

Summary

How does Syndax Pharmaceuticals compare to Xenon Pharmaceuticals?

Is XENE or SNDX more profitable?

Does the media refer more to XENE or SNDX?

Which has higher earnings & valuation, XENE or SNDX?

Do insiders and institutionals believe in XENE or SNDX?

Which has more volatility and risk, XENE or SNDX?

Do analysts prefer XENE or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Dianthus Therapeutics?

Does the media prefer DNTH or SNDX?

Is DNTH or SNDX more profitable?

Do insiders & institutionals hold more shares of DNTH or SNDX?

Do analysts recommend DNTH or SNDX?

Which has better earnings and valuation, DNTH or SNDX?

Which has more volatility and risk, DNTH or SNDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools